Investigating new therapies for chronic graft-versus-host disease (cGVHD)
Metabolomics of cGVHD
This study is looking for new and better treatments for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant, by exploring how certain immune cells work together and finding out which drugs might help those who haven't had success with regular treatments.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10914141 on NIH RePORTER |
What this research studies
This research focuses on developing innovative treatments for chronic graft-versus-host disease (cGVHD), a serious condition that can occur after allogeneic stem cell transplants. The team is studying the interactions between T cells and B cells that contribute to cGVHD and its associated complications, such as bronchiolitis obliterans, which severely affects lung function. By understanding the metabolic demands of specific immune cells involved in cGVHD, the researchers aim to identify the most effective drug therapies for patients who do not respond to standard treatments. The research includes both laboratory models and clinical trials to evaluate new therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have developed chronic graft-versus-host disease after an allogeneic stem cell transplant.
Not a fit: Patients who have not undergone stem cell transplants or those with acute graft-versus-host disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from cGVHD, potentially improving their quality of life and survival rates.
How similar studies have performed: Previous research has shown promise in developing therapies for cGVHD, with some approaches already leading to FDA-approved treatments.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Blazar, Bruce R — Dana-Farber Cancer Inst
- Study coordinator: Blazar, Bruce R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.